You have received a diagnosis of Cáncer de pulmón. After taking some time to process this, the conversation next turns to discussing lung cancer treatment. It can be very overwhelming trying to understand the various options available and what’s appropriate for you.
Terms like immunotherapy vs. chemotherapy for lung cancer get used in the same breath. But knowing what sets these two treatments apart and how they each apply to treating lung cancer can help you walk into your next conversation with your care team feeling more prepared.
You don't need to become a medical expert overnight when it comes to treating lung cancer. What you do need, though, is a clear picture of the most up-to-date treatment options in order to ask the right questions, weigh your options and feel like an active part of your own care.
According to the American Cancer Society, more than 200,000 new lung cancer cases are expected to be diagnosed in the United States, making it the second most common cancer type for both women and men (behind breast cancer and prostate cancer).
While lung cancer continues to be the leading cause of cancer death, there is a shift happening. The survival rates for certain stages have improved significantly over the past decade. Much of that progress can be traced back to innovative advances in treatment, including the rise of immunotherapy.
For people diagnosed with Stage III lung cancer that cannot be removed with surgery, the five-year survival rate has improved dramatically, from roughly 15% with chemotherapy and radiation alone to over 40% when immunotherapy is added after treatment. That means more than twice as many people are living five years or longer compared to a decade ago.
Quimioterapia and immunotherapy are both used in lung cancer treatment, but they work in different ways. Understanding the basics of each treatment can help you make sense of what your care team is recommending and why.
Chemotherapy has been a cornerstone of cancer treatment for decades. It works by targeting cells that grow and divide rapidly, which is a defining characteristic of cancer cells. But because other fast-dividing cells in your body, such as those in your hair, digestive tract and bone marrow, also share that characteristic, chemotherapy can affect them too. This is what causes many of the side effects chemotherapy is known for, such as hair loss and nausea.
Chemotherapy is typically delivered intravenously, meaning through an IV, and is given in cycles with rest periods in between to allow your body to recover. In some cases, it's given in pill form.
For lung cancer specifically, chemotherapy has been used in several ways:
Common side effects of chemotherapy can include fatigue, nausea, hair loss and an increased risk of infection. These vary widely from person to person and depend on the specific drugs used. Your care team will monitor you closely and can offer support to manage many of these side effects throughout your treatment.
Immunotherapy takes a different approach than chemotherapy. Rather than attacking cancer cells directly, it works with your immune system to help it recognize and fight the cancer on its own.
The most widely used immunotherapy drugs for lung cancer target proteins called PD-1, PD-L1 and CTLA-4, which act like brakes on the immune system. Cancer cells often exploit these brakes to avoid being detected. Checkpoint inhibitors, a class of immunotherapy drugs that block "off" signals (or checkpoints) in the immune system, release those brakes, allowing immune cells to recognize and attack the tumor.
Unlike chemotherapy, immunotherapy is not a one-size-fits-all treatment. Whether it's likely to work for you depends largely on biological markers in your specific tumor, particularly the protein PD-L1. This is part of what makes modern lung cancer treatment more personalized than it used to be.
The side effects associated with immunotherapy are different from those of chemotherapy. Because it activates your immune system, it can sometimes cause it to become overactive, leading to inflammation in organs like the lungs, liver or colon. These immune-related side effects are generally manageable, especially when caught early, which is why regular check-ins with your care team matter.
| Treatment feature | Quimioterapia | Immunotherapy |
|---|---|---|
| Cómo funciona | Attacks rapidly dividing cells throughout the body, including cancer cells. | Helps the immune system recognize and attack cancer cells more effectively. |
| What it targets | Cancer cells and some healthy fast-growing cells. | Specific immune pathways involved in cancer growth and survival. |
| Common side effects | Nausea, fatigue, hair loss, lowered blood counts and increased infection risk. | Fatigue, rash, diarrhea and immune-related inflammation that can affect organs such as the lungs, liver or thyroid. |
| Who may receive it | Often an option regardless of tumor biomarkers or genetic characteristics. | Typically recommended when certain biomarkers are present. |
| Duration of response | Generally works while treatment is being administered. | May provide longer-lasting responses in some patients by helping the immune system continue recognizing cancer cells. |
| How it is given | Usually administered through IV infusions, though some medications are taken orally. | Most commonly given through IV infusions on a regular treatment schedule. |
| Can it be combined with other treatments? | Frequently combined with surgery, radiation therapy, targeted therapy or immunotherapy. | Often used alone or in combination with chemotherapy and other treatments. |
Keep in mind that every person's treatment plan is different. Your oncologist will recommend the approach that best fits the type and stage of your lung cancer, biomarker testing results, your overall health and treatment goals.
Lung cancer isn't a single condition. The two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), respond differently to treatment. Your care team uses a multidisciplinary approach, drawing together oncologists, pulmonologists, thoracic surgeons and other specialists to build a treatment plan around your specific diagnosis.
Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses. Over the past decade, immunotherapy has become a central part of how advanced NSCLC is treated, often in combination with chemotherapy. A clinical trial showed that combining immunotherapy with chemotherapy before surgery led to significantly better outcomes in people with operable NSCLC, and this approach is now considered a standard of care in eligible cases.
For people with a high PD-L1 protein expression, immunotherapy alone (without chemotherapy) may be an option. Research has shown a five-year overall survival rate of over 31% with immunotherapy alone in this group, compared to roughly 16% with chemotherapy. For those with lower PD-L1 expression, a combination of immunotherapy and chemotherapy tends to produce stronger results.
Small cell lung cancer (SCLC) is a faster-growing form of the condition that has been harder to treat. For many years, chemotherapy was the primary option. Immunotherapy has been introduced more recently into SCLC treatment, and clinical data shows that adding immunotherapy to standard chemotherapy regimens improves survival outcomes in certain cases. Three-year survival rates in SCLC have risen from under 6% with chemotherapy alone to around 17.6% when immunotherapy is added, a notable move for a condition that once offered very limited options beyond traditional chemotherapy.
One of the most significant developments in lung cancer treatment in recent years has been the recognition that you don’t have to choose between immunotherapy vs. chemotherapy. For many people, a combination of both is now the recommended starting point.
Chemotherapy and immunotherapy complement each other in a specific way. Chemotherapy causes cancer cells to release proteins that help the immune system identify them, making the tumor more visible to the immunotherapy drugs. This combination has consistently shown better survival outcomes in clinical trials than either treatment on its own for most stages and types of lung cancer.
A clinical trial found that people who received immunotherapy combined with chemotherapy had a 24-month event-free survival rate of 62.4%, compared to 40.6% for those who received chemotherapy alone. These numbers reflect just how much the treatment landscape has transformed.
When meeting with your oncologist to discuss lung cancer treatment options, it can help to have a few questions prepared to make the conversation more productive. Bringing a trusted person with you to take notes can also help, since it's easy to feel overwhelmed when processing a lot of information at once.
Here are some questions worth considering:
The conversation around lung cancer treatment has changed, and it continues to evolve. The gap between what was possible a decade ago and what's possible today is substantial.
Whether your care team recommends chemotherapy, immunotherapy or a combination of both, the goal is always the same: determining the most effective treatment approach for your specific situation.
Learning the difference between chemotherapy and immunotherapy for treating lung cancer helps you participate more fully in that decision. The more you understand your options, the better equipped you'll be to ask the questions that matter most to you for a better outcome.
Questions about your lung cancer treatment options? Connect with a patient navigator today.
La atención médica no tiene por qué ser difícil. Constantemente buscamos maneras de hacerlo más fácil para que usted pueda mejorar y permanecer así.
Todos tenemos diferentes necesidades de atención médica. Manéjelos a su manera con la aplicación MyBSWHealth. Descargue la aplicación hoy y adopte un enfoque práctico para su atención médica.
